The collaboration will see Exothera use its scale-X technology to develop Vaccizone’s COVID-19 vaccine to produce clinical material for clinical trials and toxicological studies. The deal will see Exothera provide Vaccizone its full-service offering, which includes upstream and downstream process development, plasmid supply, and production. Additionally, the single partnership approach will facilitate small scale to drug substance and drug product manufacturing, paired with analytical toolkit assays set-up, CMC support, control validation, and DSP process development. “Clinical manufacturing is expected to…